vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and Eightco Holdings Inc. (ORBS). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $10.2M, roughly 1.4× Eightco Holdings Inc.). FENNEC PHARMACEUTICALS INC. runs the higher net margin — -34.7% vs -2281.6%, a 2246.9% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs -49.9%). Over the past eight quarters, Eightco Holdings Inc.'s revenue compounded faster (13.1% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
FENC vs ORBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $10.2M |
| Net Profit | $-4.8M | $-232.5M |
| Gross Margin | — | -13.0% |
| Operating Margin | -18.5% | -475.0% |
| Net Margin | -34.7% | -2281.6% |
| Revenue YoY | 73.8% | -49.9% |
| Net Profit YoY | -141.1% | -9183.3% |
| EPS (diluted) | $-0.17 | $-2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $10.2M | ||
| Q3 25 | $12.5M | $5.3M | ||
| Q2 25 | $9.7M | $7.6M | ||
| Q1 25 | $8.8M | $9.9M | ||
| Q4 24 | $7.9M | $20.3M | ||
| Q3 24 | $7.0M | $6.1M | ||
| Q2 24 | $7.3M | $5.3M | ||
| Q1 24 | $25.4M | $8.0M |
| Q4 25 | $-4.8M | $-232.5M | ||
| Q3 25 | $-638.0K | $-25.8M | ||
| Q2 25 | $-3.2M | $-1.2M | ||
| Q1 25 | $-1.2M | $-2.5M | ||
| Q4 24 | $-2.0M | $-2.5M | ||
| Q3 24 | $-5.7M | $-3.2M | ||
| Q2 24 | $-5.6M | $4.4M | ||
| Q1 24 | $12.8M | $1.9M |
| Q4 25 | — | -13.0% | ||
| Q3 25 | — | -3.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | 26.5% | ||
| Q2 24 | — | 25.1% | ||
| Q1 24 | — | 17.5% |
| Q4 25 | -18.5% | -475.0% | ||
| Q3 25 | -1.5% | -116.9% | ||
| Q2 25 | -28.3% | -15.9% | ||
| Q1 25 | -9.2% | -14.3% | ||
| Q4 24 | -11.8% | -11.9% | ||
| Q3 24 | -74.6% | -29.1% | ||
| Q2 24 | -69.4% | -16.4% | ||
| Q1 24 | 54.2% | -39.6% |
| Q4 25 | -34.7% | -2281.6% | ||
| Q3 25 | -5.1% | -487.6% | ||
| Q2 25 | -32.7% | -15.4% | ||
| Q1 25 | -13.3% | -25.7% | ||
| Q4 24 | -25.0% | -12.3% | ||
| Q3 24 | -82.2% | -52.5% | ||
| Q2 24 | -76.5% | 84.2% | ||
| Q1 24 | 50.6% | 24.4% |
| Q4 25 | $-0.17 | $-2.34 | ||
| Q3 25 | $-0.02 | $-0.58 | ||
| Q2 25 | $-0.11 | $-0.38 | ||
| Q1 25 | $-0.04 | $-0.84 | ||
| Q4 24 | $-0.02 | $-1.44 | ||
| Q3 24 | $-0.21 | $-1.77 | ||
| Q2 24 | $-0.20 | $2.15 | ||
| Q1 24 | $0.41 | $1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | $58.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $35.5M | $232.6M |
| Total Assets | $70.6M | $250.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | $58.5M | ||
| Q3 25 | $21.9M | $23.7M | ||
| Q2 25 | $18.7M | $696.3K | ||
| Q1 25 | $22.7M | $434.4K | ||
| Q4 24 | $26.6M | $239.2K | ||
| Q3 24 | $40.3M | $2.4M | ||
| Q2 24 | $43.1M | $363.1K | ||
| Q1 24 | $51.2M | $808.8K |
| Q4 25 | — | — | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $232.6M | ||
| Q3 25 | $-4.5M | $339.2M | ||
| Q2 25 | $-7.5M | $8.9M | ||
| Q1 25 | $-5.9M | $9.7M | ||
| Q4 24 | $-5.9M | $11.9M | ||
| Q3 24 | $-5.2M | $13.0M | ||
| Q2 24 | $-1.4M | $13.8M | ||
| Q1 24 | $3.0M | $3.9M |
| Q4 25 | $70.6M | $250.2M | ||
| Q3 25 | $49.3M | $355.5M | ||
| Q2 25 | $44.9M | $48.7M | ||
| Q1 25 | $46.4M | $47.6M | ||
| Q4 24 | $44.9M | $50.8M | ||
| Q3 24 | $58.9M | $49.2M | ||
| Q2 24 | $63.2M | $48.4M | ||
| Q1 24 | $69.2M | $50.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-11.0M |
| Free Cash FlowOCF − Capex | — | $-11.0M |
| FCF MarginFCF / Revenue | — | -107.7% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-11.0M | ||
| Q3 25 | $1.5M | $-1.6M | ||
| Q2 25 | $-3.7M | $-659.2K | ||
| Q1 25 | $-4.3M | $999.8K | ||
| Q4 24 | $-1.5M | $-6.6M | ||
| Q3 24 | $-2.2M | $77.7K | ||
| Q2 24 | $-8.4M | $-440.3K | ||
| Q1 24 | $39.0M | $-723.3K |
| Q4 25 | — | $-11.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-661.3K | ||
| Q1 25 | — | $999.7K | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | — | $73.0K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -107.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8.7% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -32.7% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.10× | ||
| Q1 24 | 3.04× | -0.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
